Potential protective role of apoprotein J (clusterin) in atherogenesis: Binding to enzymatically modified low-density lipoprotein reduces fatty acid-mediated cytotoxicity

Summary

Following entrapment in the arterial intima, low-density lipoprotein (LDL) can be modified by hydrolytic enzymes to yield a lipoprotein derivative that binds C-reactive protein, activates complement, and is rapidly taken up by monocytes/macrophages. Free fatty acids contained in enzymatically modified LDL (E-LDL) render the lipoprotein cytotoxic due to their capacity to trigger programmed cell death. Apoprotein J (ApoJ) alias clusterin is a multifunctional glycoprotein with cytoprotective and anti-inflammatory properties. It interacts with diverse substrates, is present in the intima and the media of arteries with atherosclerotic lesions and is also synthesized by smooth muscle cells during development of atherosclerosis. We report that ApoJ binds to E-LDL but not to native LDL. Binding resulted in marked reduction of cytotoxicity of E-LDL on smooth muscle cells, as revealed by determination of caspase activity, annexin binding, and cellular ATP. ApoJ was detected immunohistochemically in early atherosclerotic lesions, where it was found to colocalize with E-LDL. In atherosclerotic lesions, ApoJ may thus subserve protective functions through its capacity to inactivate C5b-9 complement complexes and by reducing the cytotoxic effects of modified LDL on cells that gain contact with the lipoprotein.

Keywords

Apoptosis - atherosclerosis - apolipoprotein J - clusterin - low-density lipoprotein

^* These authors contributed equally to this work.

• References

• 1 Ross R. Atherosclerosis--an inflammatory disease. N Engl J Med 1999; 340: 115-126.
• 2 Glass CK, Witztum JL. Atherosclerosis. the road ahead. Cell 2001; 104: 503-516.
• 3 Libby P. Inflammation in atherosclerosis. Nature 2002; 420: 868-874.
• 4 Freire de Carvalho J, Sherer Y. et al. The fine-tuning of anti-oxidized low-density lipoprotein antibodies in cardiovascular disease and thrombosis. Thromb Haemost 2007; 98: 1157-1159.
• 5 Soltesz P, Veres K, Laczik R. et al. Evaluation of antibodies to oxidized low-density lipoprotein and assessment of C-reactive protein in acute coronary syndrome and stable coronary artery disease. Thromb Haemost 2007; 98: 413-419.
• 6 Kruth HS. Localization of unesterified cholesterol in human atherosclerotic lesions. Demonstration of filipin-positive, oil-red-O-negative particles. Am J Pathol 1984; 114: 201-208.
• 7 Kruth HS. Subendothelial accumulation of unesterified cholesterol. An early event in atherosclerotic lesion development. Atherosclerosis 1985; 57: 337-341.
• 8 Simionescu N, Vasile E, Lupu F. et al. Prelesional events in atherogenesis. Accumulation of extracellular cholesterol-rich liposomes in the arterial intima and cardiac valves of the hyperlipidemic rabbit. Am J Pathol 1986; 123: 109-125.
• 9 Chao FF, Amende LM, Blanchette-Mackie EJ. et al. Unesterified cholesterol-rich lipid particles in atherosclerotic lesions of human and rabbit aortas. Am J Pathol 1988; 131: 73-83.
• 10 Frank JS, Fogelman AM. Ultrastructure of the intima in WHHL and cholesterol-fed rabbit aortas prepared by ultra-rapid freezing and freeze-etching. J Lipid Res 1989; 30: 967-978.
• 11 Seifert PS, Hugo F, Tranum-Jensen J. et al. Isolation and characterization of a complement-activating lipid extracted from human atherosclerotic lesions. J Exp Med 1990; 172: 547-557.
• 12 Steinbrecher UP, Lougheed M. Scavenger receptor-independent stimulation of cholesterol esterification in macrophages by low density lipoprotein extracted from human aortic intima. Arterioscler Thromb 1992; 12: 608-625.
• 13 Bhakdi S, Dorweiler B, Kirchmann R. et al. On the pathogenesis of atherosclerosis: enzymatic transformation of human low density lipoprotein to an atherogenic moiety. J Exp Med 1995; 182: 1959-1971.
• 14 Han SR, Momeni A, Strach K. et al. Enzymatically modified LDL induces cathepsin H in human monocytes: potential relevance in early atherogenesis. Arterioscler Thromb Vasc Biol 2003; 23: 661-667.
• 15 Hakala JK, Oksjoki R, Laine P. et al. Lysosomal enzymes are released from cultured human macrophages, hydrolyze LDL in vitro, and are present extracellularly in human atherosclerotic lesions. Arterioscler Thromb Vasc Biol 2003; 23: 1430-1436.
• 16 Torzewski M, Suriyaphol P, Paprotka K. et al. Enzymatic modification of low-density lipoprotein in the arterial wall: a new role for plasmin and matrix metalloproteinases in atherogenesis. Arterioscler Thromb Vasc Biol 2004; 24: 2130-2136.
• 17 Torzewski M, Klouche M, Hock J. et al. Immunohistochemical demonstration of enzymatically modified human LDL and its colocalization with the terminal complement complex in the early atherosclerotic lesion. Arterioscler Thromb Vasc Biol 1998; 18: 369-378.
• 18 Kruth HS, Zhang WY, Skarlatos SI. et al. Apolipoprotein B stimulates formation of monocyte-macrophage surface-connected compartments and mediates uptake of low density lipoprotein-derived liposomes into these compartments. J Biol Chem 1999; 274: 7495-7500.
• 19 Kapinsky M, Torzewski M, Buchler C. et al. Enzymatically degraded LDL preferentially binds to CD14(high) CD16(+) monocytes and induces foam cell formation mediated only in part by the class B scavenger-receptor CD36. Arterioscler Thromb Vasc Biol 2001; 21: 1004-1010.
• 20 Bhakdi S, Torzewski M, Klouche M. et al. Complement and atherogenesis: binding of CRP to degraded, nonoxidized LDL enhances complement activation. Arterioscler Thromb Vasc Biol 1999; 19: 2348-2354.
• 21 Bhakdi S, Torzewski M, Paprotka K. et al. Possible protective role for C-reactive protein in atherogenesis: complement activation by modified lipoproteins halts before detrimental terminal sequence. Circulation 2004; 109: 1870-1876.
• 22 Suriyaphol P, Fenske D, Zahringer U. et al. Enzymatically modified nonoxidized low-density lipoprotein induces interleukin-8 in human endothelial cells: role of free fatty acids. Circulation 2002; 106: 2581-2587.
• 23 Dersch K, Ichijo H, Bhakdi S. et al. Fatty acids liberated from low-density lipoprotein trigger endothelial apoptosis via mitogen-activated protein kinases. Cell Death Differ 2005; 12: 1107-1114.
• 24 Bhakdi S, Lackner KJ, Han SR. et al. Beyond cholesterol: the enigma of atherosclerosis revisited. Thromb Haemost 2004; 91: 639-645.
• 25 Koch-Brandt C, Morgans C. Clusterin: A role for cell survival in the face of apoptosis?. In: Progress in Molecular und Subcellular Biology. Berlin-Heidelberg-New York: Springer Verlag; 1995: 130-149.
• 26 Rosenberg ME, Silkensen J. Clusterin: physiologic and pathophysiologic considerations. Int J Biochem Cell Biol 1995; 27: 633-645.
• 27 Ishikawa Y, Akasaka Y, Ishii T. et al. Distribution and synthesis of apolipoprotein J in the atherosclerotic aorta. Arterioscler Thromb Vasc Biol 1998; 18: 665-672.
• 28 Jenne DE, Tschopp J. Molecular structure and functional characterization of a human complement cytolysis inhibitor found in blood and seminal plasma: identity to sulfated glycoprotein 2, a constituent of rat testis fluid. Proc Natl Acad Sci USA 1989; 86: 7123-7127.
• 29 Kirszbaum L, Sharpe JA, Murphy B. et al. Molecular cloning and characterization of the novel, human complement-associated protein, SP-40,40: a link between the complement and reproductive systems. Embo J 1989; 08: 711-718.
• 30 McDonald JF, Nelsestuen GL. Potent inhibition of terminal complement assembly by clusterin: characterization of its impact on C9 polymerization. Biochemistry 1997; 36: 7464-7473.
• 31 Witte DP, Aronow BJ, Stauderman ML. et al. Platelet activation releases megakaryocyte-synthesized apolipoprotein J, a highly abundant protein in atheromatous lesions. Am J Pathol 1993; 143: 763-773.
• 32 Jordan-Starck TC, Lund SD, Witte DP. et al. Mouse apolipoprotein J: characterization of a gene implicated in atherosclerosis. J Lipid Res 1994; 35: 194-210.
• 33 Urban J, Parczyk K, Leutz A. et al. Constitutive apical secretion of an 80-kD sulfated glycoprotein complex in the polarized epithelial Madin-Darby canine kidney cell line. J Cell Biol 1987; 105: 2735-2743.
• 34 de Silva HV, Stuart WD, Duvic CR. et al. A 70-kDa apolipoprotein designated ApoJ is a marker for subclasses of human plasma high density lipoproteins. J Biol Chem 1990; 265: 13240-13247.
• 35 Jenne DE, Lowin B, Peitsch MC. et al. Clusterin (complement lysis inhibitor) forms a high density lipoprotein complex with apolipoprotein A-I in human plasma. J Biol Chem 1991; 266: 11030-11036.
• 36 Calero M, Tokuda T, Rostagno A. et al. Functional and structural properties of lipid-associated apolipoprotein J (clusterin). Biochem J 1999; 344: 375-383.
• 37 Morrissey C, Lakins J, Moquin A. et al. An antigen capture assay for the measurement of serum clusterin concentrations. J Biochem Biophys Methods 2001; 48: 13-21.
• 38 Gelissen IC, Hochgrebe T, Wilson MR. et al. Apolipoprotein J (clusterin) induces cholesterol export from macrophage-foam cells: a potential anti-atherogenic function?. Biochem J 1998; 331: 231-237.
• 39 Losch A, Koch-Brandt C. Dithiothreitol treatment of Madin-Darby canine kidney cells reversibly blocks export from the endoplasmic reticulum but does not affect vectorial targeting of secretory proteins. J Biol Chem 1995; 270: 11543-11548.
• 40 Sivamurthy N, Stone DH, Logerfo FW. et al. Apolipoprotein J inhibits the migration, adhesion, and proliferation of vascular smooth muscle cells. J Vasc Surg 2001; 34: 716-723.
• 41 Kelso GJ, Stuart WD, Richter RJ. et al. Apolipoprotein J is associated with paraoxonase in human plasma. Biochemistry 1994; 33: 832-839.
• 42 Navab M, Hama-Levy S, Van Lenten BJ. et al. Mildly oxidized LDL induces an increased apolipoprotein J/paraoxonase ratio. J Clin Invest 1997; 99: 2005-2019.
• 43 Navab M, Anantharamaiah GM, Reddy ST. et al. An oral apoJ peptide renders HDL antiinflammatory in mice and monkeys and dramatically reduces atherosclerosis in apolipoprotein E-null mice. Arterioscler Thromb Vasc Biol 2005; 25: 1932-1937.
• 44 Matsuda A, Itoh Y, Koshikawa N. et al. Clusterin, an abundant serum factor, is a possible negative regulator of MT6-MMP/MMP-25 produced by neutrophils. J Biol Chem 2003; 278: 36350-36357.
• 45 Santilli G, Aronow BJ, Sala A. Essential requirement of apolipoprotein J (clusterin) signaling for IkappaB expression and regulation of NF-kappaB activity. J Biol Chem 2003; 278: 38214-38219.
• 46 Artwohl M, Roden M, Waldhausl W. et al. Free fatty acids trigger apoptosis and inhibit cell cycle progression in human vascular endothelial cells. Faseb J 2004; 18: 146-148.
• 47 Essayagh S, Xuereb JM, Terrisse AD. et al. Microparticles from apoptotic monocytes induce transient platelet recruitment and tissue factor expression by cultured human vascular endothelial cells via a redox-sensitive mechanism. Thromb Haemost 2007; 98: 831-837.
• 48 Abid Hussein MN, Boing AN, Sturk A. et al. Inhibition of microparticle release triggers endothelial cell apoptosis and detachment. Thromb Haemost 2007; 98: 1096-1107.